Boston Therapeutics Initiates Clinical Study at Sydney University to Evaluate sugardown(R) With Sugary Beverage Consumption

Study Is First to Measure Potential of sugardown(R) to Reduce Glucose and Insulin Levels Following Consumption of Sugary BeveragesMANCHESTER, NH, Nov 17, 2014 (Marketwired via COMTEX) Boston Therapeutics, Inc. (OTCQB: BTHE) ( Boston Therapeutics or the Company ), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and SugarDown Co Ltd (Hong Kong), are jointly sponsoring a study, which was initiated this week at Sydney University s Glycemic Index Research Service (SUGiRS), to determine postprandial glucose and insulin response to soft drink consumption with sugardown(R). This is the first study to evaluate sugardown(R) s effectiveness with sugary beverages. The single-center, randomized, controlled, crossover study is being conducted at SUGiRS. A total of 10 healthy, overweight adults are being enrolled in the study. The subjects will be administered three test portions: a serving of Sprite(R) soft drink containing 50 grams of carbohydrate; an
http://bit.ly/1vqtQjJ